Genmab — August 2014
-
Meddelse ovre på Euroinvestor: The company and capital he runs requires to make decisions on many aspects. One of which can be the need for liquidity.
-
spoke with Mr Stienstra yesterday. All shares are absorbed in the market over the past few months with no significant effect on the share price as a result of his sale.
Sale has no relation with the confidence in Genmab. -
ja 233 nu. Men den har bare mega modstand i 240-255 nivauet... Kan den kæmpe sig derover (ca. 10% mere) er der så til gengæld også virkelig åbent opad
-
Når man ser hvor hurtigt Janssen gør fremskridt med DuoBody, så undrer det mig lidt at Kirin og efterhånden også Lilly samarbejdet kører så længe uden det munder ud i mere ! Der kan selvfølgelig ligge forskellige forklaringer i at se teknologien an, meeeeeen så lang tid kan det vel heller ikke tage.
-
ja jeg savner bare en licensaftale mere. En med upfront betaling og en samlet milestonepakke
-
den sidste vi fik af denne var altså jannsen i juli 2012 !!!
-
hvis man ikke tæller "udvidelsen" af Jannsen aftalen med som de lavede sidste år
Det bliver spændende at få kastet lys over de pivotal 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind